HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

The Impact of America COMPETES Act on China Healthcare – Supply Chain Decoupling?

China CXO Has Reached a Crossroads - Time to Reconsider

About the CXO Plunge After Biden Signed National Biotechnology and Biomanufacturing Initiative

Gravity Works As WeWork Doesn't; Now Plan B

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>The assassination of Trump in July has greatly increased the probability of his election as president this year. However, a Trump presidency is not necessarily good for healthcare industry.</li>
<li>Trump's reform in the field of healthcare has two major propositions - One is to achieve the independence of US pharmaceutical supply chain. The other is to reduce drug prices.</li>
<li>From a US national security perspective, China's APIs/CXO would be the segments with the highest sanction risk. China Biotech may also face some headwinds. The risk of "decoupling" further increases.</li>
</ul>


The assassination of Trump in July has greatly increased the probability of his election as president this year. However, a Trump presidency is not necessarily good for healthcare industry.
Trump's reform in the field of healthcare has two major propositions - One is to achieve the independence of US pharmaceutical supply chain. The other is to reduce drug prices.
From a US national security perspective, China's APIs/CXO would be the segments with the highest sanction risk. China Biotech may also face some headwinds. The risk of "decoupling" further increases.


Shanghai Fosun Pharmaceutical (Group) (2196 HK)

Zhejiang Hisun Pharmaceutical Co, Ltd. (600267 CH)

Zhejiang Huahai Pharmaceutical Co, Ltd. (600521 CH)

What Does a Trump Presidency Mean for China Healthcare?